EU approves new osteoporosis treatment
Amgen and UCB’s Evenity has been given the green light for postmenopausal women with severe osteoporosis to help prevent further fractures
Read More
Tag: romosozumab
UCB, Amgen refile osteoporosis drug Evenity
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
Read More
UCB, Amgen’s Evenity under review in Europe
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
Read More
US regulators turn away Amgen/UCB’s bone drug Evenity
Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators.
Read More
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
